Dr. Farid Gholitabar, MD

Dr. Gholitabar practices at Cimpar, S.c. in Oak Park, Illinois.

Dr. Gholitabar's NPI, 1801278650, was assigned on June 28, 2015. Dr. Gholitabar holds Illinois license 036.148284.

Dr. Gholitabar's primary practice is Cimpar, S.c., at 101 Madison St Ste 300 Suite 300, Oak Park, IL 60302. The practice phone is (708) 486-2700.

Dr. Gholitabar's primary practice is Cimpar, S.c. in Oak Park, Illinois. The medical group on file is CIMPAR, S.C.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gholitabar practices. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Gholitabar's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Gholitabar is licensed in Illinois.

CMS data shows 703 Medicare services from Dr. Gholitabar across 4 procedure codes in 2024, for 341 Medicare patients. Medicare paid $55,958 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 341 Medicare patients who saw Dr. Gholitabar in 2024. The largest group is 75 to 84, with 139 patients. 75% of them have arthritis, and 75% have high blood pressure. 38% are also on Medicaid. Their average risk score is 2.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gholitabar's median patient age at 82, with 64% women.

In 2024, Dr. Gholitabar wrote 113 Medicare Part D claims for 31 patients. 87% of them were for generic drugs. CMS names the drug for 60 of them, across 4 drugs with 11 or more claims each, at $689 in total drug cost. In 2023, CMS named 46 claims across 2 drugs.

Dr. Gholitabar accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Gholitabar. Dr. Gholitabar's most frequent co-authors are Lili Chan, MD, Davendra Mehta, MD and Ira S. Meisels, MD.

CMS Open Payments shows 12 general payments to Dr. Gholitabar from 7 drug and device companies from 2020 to 2024. Food and beverage make up the largest share, 69% of the total. Amgen Inc. paid the most, $411.